• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Bye-Bye China?

    Decentralized Trials Fuel AI Revolution in Clinical Research

    Self-Medication: Flexibility for Patients and Drug Manufacturers

    The Single-Use Mixing Landscape: Evaluating Your Options

    DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Pfizer, BioNTech Enter Vax Pact with COVAX

    FDA Approves Janssen’s CABENUVA

    AGC Biologics Appoints Boulder Site GM

    Lilly Completes $1B Acquisition of Prevail

    Top BioPharma Form Accumulus Synergy
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Integrated Continuous Manufacturing ICM

    CONTINUUS Awarded $69.3M DoD Grant

    WDSrx Expands Warehouse Network

    Piramal Inks Clinical Supply Deal with Theratechnologies

    Recipharm Signs Manufacturing Deal with Enzymatica
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    WDSrx Expands Warehouse Network

    Catalent Acquires Acorda’s INBRIJA Manufacturing Operations

    Varcode, PL Developments Form Strategic ‘Smart Tag’ Pact

    COVID-19 Vaccine Distribution: The Air Cargo Industry’s Greatest Challenge

    Thermo Fisher Expands Clinical Supply Services in Europe
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Lilly Completes $1B Acquisition of Prevail

    Top BioPharma Form Accumulus Synergy

    Coating Place Wurster Fluid Bed Process Scaling

    AbbVie Licenses ProBioGen’s GlymaxX Technology

    Improving Product Profitability
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Syngene

    Emergent BioSolutions

    Baxter BioPharma Solutions

    Almac Group

    Alcami
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Alcami

    Emergent BioSolutions

    Reed-Lane

    Aphena Pharma Solutions

    Almac Group
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Ensuring Drug Quality in a Global Economy

    Offshore CMO’s have proven a weak link in pharma’s supply chain. Will recent quality problems in India and China increase oversight?

    Related CONTENT
    • Mogene
    • Recro Gainesville Expands Mfg. Capabilities
    • Diverse Products And Technologies Delivered
    • PPD Expands Vaccine Development Lab
    • UPM Celebrates 100-Years of Mfg. at Tennessee Site
    Helena Champion , Principal Consultant, Drug Quality Assurance LLC05.01.14
    Conventional economic wisdom holds that low cost producers anywhere in the world can make any product more economically than established manufacturers in countries with mature economies. This is not always the case with pharmaceuticals. Whether name-brand or generic drugs are involved, it takes enormous and complex effort by any manufacturer to follow current good manufacturing practices (cGMPs). There is no safe way around these regulations, which were designed to ensure drug safety and efficacy, correct amount of active pharmaceutical ingredients (APIs), and the absence of contamination. Injectable drugs also require sterile conditions during manufacturing.

    The desire to reduce costs has led to an increase in the number of pharmaceuticals and APIs manufactured and sourced from abroad, notably from India and China. The U.S FDA estimates that roughly 80 percent of APIs and 40 percent of finished drugs sold in the U.S. come from foreign sources. Western companies seeking to cut costs buy drugs and materials from these companies and market them under their own labels. However, recent regulatory inspection reports have described serious cGMP problems at some Indian and Chinese facilities.

    Developed nations such as the U.S. and Japan have set stringent quality requirements for pharmaceutical manufacturing, as has the European Medicines Agency (EMA), comprising the U.K. and about thirty European and Nordic countries.  However, over the past seven years, we’ve seen a steady flow of bad news about quality and compliance from parts of the world with less strict pharmaceutical manufacturing regulations.

    Incidents ranged from the contaminated heparin sourced from China, which led to over 200 patient deaths worldwide1,2, to glass particles in Ranbaxy’s atorvastatin, to a Consent Decree for Ranbaxy and Warning Letters to Wockhardt and others. Charges included lack of data integrity, and efforts to make products appear to be of good quality when they weren’t.

    One recent article stated that  “a handful” of FDA Warning Letters had been issued to Indian manufacturers since 2011. In fact, over 25 were sent during that period (Table 2) and, within the past five years, at least 75 Indian and 84 Chinese companies have
    either received FDA Warning Letters, been placed under Consent Decree, put on the FDA Import Alert List banning entry of their products into the U.S, or placed on the EMA’s noncompliance list, all for serious GMP failures. In addition, 13 other Indian facilities not shown on Table 2 are now on the FDA Import Alert list.

    Although the FDA is trying to pinpoint the exact figure, at this point, nobody really knows how many foreign companies supply drugs to the U.S. In 2011, the India Chamber of Commerce estimated that 120 Indian drug manufacturing plants3 supplied the U.S. 
    Bloomberg News4 recently reported that over 500 Indian drug companies had registered with the FDA. However,  registration does not imply FDA approval—anyone with internet access can register and it does not require inspection.

    While the public and legislators may occasionally read something about quality problems, few know whether the quality problems reported by the FDA and EMA matter, or how widespread they are.

    The GMP failures described by the FDA and EMA are not trivial, but go to the heart of safety and efficacy.  They include:
    • falsification and fabrication of data to make a substandard drug appear to be of good quality blending failing API batches with good batches
    • not following procedures to protect drugs from contamination
    • not reporting microbiological contamination
    • not following aseptic procedures while making injectable drugs
    • retesting and manipulating samples that failed quality tests until passing results were obtained
    • documenting manufacturing and testing data before actual manufacturing and testing.
    Table 1 summarizes the number of companies found noncompliant by the FDA and the EMA.

    It is encouraging to note that data falsification rarely happens anymore in the U.S. or Europe. Notable exceptions occurred at Impax Laboratories in Hayward, CA. The company’s CEO, Chungchiang Hsu, received a 483 from FDA for labs doing “trial samples,” apparently in order to create good HPLC results to report for a batch. The Barr Laboratories decision in 1993 made clear that this practice would not be tolerated, and drug companies in strictly regulated countries take this seriously.

    Consumers seldom know who made their drugs or where they were made
    The fact is that, in the U.S., consumers have no idea whether the drugs and dietary supplements they buy are made properly or not,  who made them and where or how they were made. The name on the package is seldom that of the actual manufacturer of the drug inside the package and the address is very seldom that of the actual manufacturer.

    Most prescription and over-the-counter (OTC) drugs and dietary supplements, even those with well known brand names, are made by contract manufacturing organizations (CMO’s), not by the company or distributer that markets the drug. 

    Even doctors and pharmacists will seldom know where, or by whom, a drug that they prescribe is made. When the consumer buys an OTC drug such as aspirin or ibuprofen or a multivitamin tablet, the package states who distributes it, not where it was made or who made it.  Thus, consumers have no way of protecting themselves, not only because they lack information, but they not be well enough at the time of dosing to even try to make an informed choice.  The hospital patient, for instance, has no idea where his or her intravenous medication comes from. 

    The identity and location of the actual facility where a drug is made is confidential, disclosed only to the FDA or other country’s regulatory authority.

    Let’s look at some persistent myths about drug quality and access, and contrast them with realities.

    Myth – FDA or Some Independent Body Tests All Drugs That Enter the U.S.
    Many consumers imagine that the FDA or some independent body tests all the drugs that come into the U.S. but that almost never happens. Drugs are received on trust, and only a thorough, in depth audit by the company marketing the drug here or a regulatory inspection by a global regulatory agency can determine whether that trust is justified.  The FDA only recently started a limited pilot program at a few universities to do limited testing for generic equivalency on drugs made domestically and overseas, but that is different from routine quality control testing.

    Fact – The Manufacturer and Marketer Decide Whether Or Not a Batch is Good
    Most consumers do not know that the manufacturer and marketer of the drug is responsible for testing it and deciding whether each batch is good or not.  This might, potentially, create a conflict of interest between the profit motive and the requirement to approve only good product and to reject and destroy bad batches.  That is why the FDA and other high standard regulatory authorities such as countries in the EMA (includes about 30 European countries) insist that manufacturers comply with cGMPs and that marketers follow regulations. Regulators perform plant inspections to verify compliance. 

    cGMPs encompass all the appropriate procedures to make and test the specific product. If the right procedures are not followed, the product may not be safe or effective. For instance, if an injectable product that should be sterile and free of pyrogens is not protected from contamination during its manufacture, then part or all of the batch may be contaminated. If the right quality and quantity of active ingredient is not used, or test results are faked, the drug may not be effective.

    The system works well at drug manufacturers that operate to high standards, such as those in the U.S., Europe, U.K. and well regulated countries, both for brand names and generics.  When selection of a CMO is based on its ability to comply with cGMP (deliver good quality, provide the right expertise, process facilities and equipment) as well as cost, the outcome is usually good. 

    Myth – Generic Drugs are Cheaper to Make
    People expect generics to be much cheaper, as well as equivalent to brand-name drugs. The reality is that generics are only equal if they are made and tested properly, using high quality materials. In reality, it requires similar facilities, equipment, similar inactive ingredients, packaging and just as much effort and care for a generic as for a branded drug. The active pharmaceutical ingredient may be cheaper, if a long established material, for example, aspirin, or salt in a saline intravenous drip, but the cost of the API is only a fraction of the overall cost of making the finished drug product. 

    If a lower cost producer uses cheap labor with insufficient training or education, mistakes may be made in manufacturing, leading to inferior product. If inferior materials, processes and procedures are used, the resulting product may not be safe or effective, in which case the “lower” initial cost comes with high costs to society, such as prolonged medical treatment and loss of productivity of the patient. There may also be significant costs to the manufacturer5.

    Generics offer savings because their marketing costs are lower, and small molecule generics require less development effort.  Generic marketing applications to regulatory agencies, especially for older, small-molecule generics, require fewer clinical trials. (Biosimilars require more development effort and expense6).

    Economies of scale will help if a particular manufacturer makes a generic drug in really large numbers, but this is seldom the case, since many competing companies make the same generics.  Often, both brand names and generic drugs are made in relatively small batch sizes using multipurpose equipment, which then needs to be cleaned to avoid cross contamination and set up to make another product, all of which costs time and money.

    Myth – Compounding Laboratories Can Make Generics Safely and at Low Cost
    Some investors regarded compounding laboratories as a lucrative investment in generics. Many were unaware of the 2009 FDA Concept Paper discussing the high rate of contamination of drugs from these labs7.

    It took years before the sad truth became known to the public and to hospitals that regularly purchased drugs from them.  This culminated in many patient deaths from fungal meningitis caused by contaminated medications in 2012 to 2013.

    Numerous compounding labs have since been inspected by the FDA and found seriously deficient, as evidenced by FDA Inspection Reports and Warning Letters. Many of these labs and the companies that ran them are now out of business, and regulations have been tightened. 

    Fact – The Extent of Substandard Indian and Chinese Drugs is Not Yet Known
    The number of FDA Warning Letters and EMA noncompliance listings for India and China understates quality problems, for many reasons:
    • The number of Warning Letters is not a good measure for China because, until December, 2013, the Chinese government did not allow many FDA Inspections8 so the known quality problems there are only the tip of the iceberg. 
    • Many Indian and Chinese suppliers that currently export to the U.S. and Europe have never been inspected.
    • Foreign inspections occur less frequently since they cost more.
    • Some foreign plants refuse entry to the FDA to inspect.
    • Some avoid inspection by not registering, even though they export to the U.S. 
    • The probability of detection of problems is lower, since a far smaller proportion of foreign companies are inspected.  In the Fiscal year ending 9/30/2013, the FDA inspected 23% of domestic drug and device facilities and only 9% of the registered foreign drug and device facilities9.
    • The data falsification found by the FDA and EMA may only be the tip of the iceberg10, since it is very hard to detect after the fact, and detection depends on timing and chance, as well as the inspector’s skill.
    • The numbers in this article may underestimate the situation, due to the difficulties in searching the various FDA web pages and due to the fact that the EMA only recently started their list and it may not be complete11, for example, Glochem was pronounced noncompliant by EMA in 2010, but is not yet on their list.
    Tables 2, 3, 4 and 5 examine FDA and EMA citations to Indian and Chinese manufacturers for inadequate cGMP complianc12 - 14.
    Companies and investors are becoming aware of the costs that come with lack of quality in manufacture and this should promote an evaluation of the real costs of sourcing from poorly regulated, non-GMP-compliant suppliers.  U.S. companies that outsource need to use the same standards for auditing all their suppliers before selection, for both API’s and drug products.  This means that auditors must be fluent in the supplier’s or CMO’s language, highly trained in cGMP’s and very thorough.  Auditors who are not fluent in the local language are inadequate, since reliance on translations slows down the audit and prevents them from seeing what is actually being done, and to assess the accuracy of translation.

    After selection of a CMO or supplier, companies need to exercise a great deal of long-term onsite oversight of manufacturing and testing of their products, using their own highly trained quality and operations people in the plant, who are fluent in the language used at the CMO facility.  Many western companies do this currently at their western CMO’s and the same approach needs to be taken at any CMO, anywhere in the world.  Doing this is epensive, but it is essential and needs to be considered part of the cost of outsourcing offshore.

    Currently, many foreign manufacturers outside of the U.S, Europe and Japan are subject to minimal regulatory control and cGMP enforcement action by their own authorities. Fewer than half of them have been inspected, even once, by FDA or EMA. 

    In the end, transparency is key. Should consumers know who makes their generic drugs and where they are made, so that they can make a choice? Please write in and let us know what you think. 

    References
    1. Chinese suppliers Tied to Tainted Heparin.  http://www.raps.org/focus-online/news/news-article-view/artocle/922/chinese-suppliers-tied-to-tainted-heparin.aspx
    2. Assuring Quality in the Global Supply Chain, Measuring risk in sourcing by Helena Champion, See more at: http://www.contractpharma.com/issues/2009-09/view_features/assuring-quality-in-the-global-supply-chain/#sthash.brP6edZc.dpufhttp://www.contractpharma.com/issues/2009-09/view_features/assuring-quality-in-the-global-supply-chain/
    3. C&EN News 1/20/2014 “Welcome to the World’s Drugstore”.  (Note: It is assumed the India Chamber of Commerce meant 120 plants exporting to U.S.in the article since the FDA does not approve manufacturing plants. The FDA only approves a marketing application for a specific drug at a specific plant after inspection and there is never blanket approval of a plant.) 
    4. Disputing Study, U.S. FDA Says Generics From Abroad Safe http://www.bloomberg.com/news/2014-03-25/disputing-study-u-s-fda-says-generics-from-abroad-safe.html
    5. Flies Found by FDA Threaten Indian Town Built on Generics 7 March 2014. http://www.bloomberg.com/news/2014-03-06/flies-found-by-fda-threaten-indian-town-built-on-generics.html
    6. Chemical & Engineering News, October 7, 2013.
    7. 03/10/2009 FDA Concept Paper: Drug Products That Present Demonstrable Difficulties for Compounding Because of Reasons of Safety or Effectiveness http://www.fda.gov/RegulatoryInformation/Legislation/FederalFoodDrugandCosmeticActFDCAct/SignificantAmendmentstotheFDCAct/FDAMA/ucm100205.htm
    8. As White House Announces Breakthrough for FDA in China, Could Warning Letters Increase? 6 December 2013, By Alexander Gaffney, RF News Editor, RAPS
    9. 2014 Annual Report on Inspections of Establishments, FDA http://www.fda.gov/downloads/regulatoryinformation/legislation/federalfooddrugandcosmeticactfdcact/significantamendmentstothefdcact/fdasia/ucm384063.pdf
    10. Do Indian Companies Have a Chronic Data Falsification Problem? FDA Warning Letters Indicate ‘Yes’. Regulatory Affairs Professional Society Latest News | Posted: 28 January 2014,  By Alexander Gaffney, RAC, see more at http://www.raps.org/focus-online/news/news-article-view/article/4548/do-indian-companies-have-a-chronic-data-falsification-problem-fda-warning-lette.aspx
    11. Press release - European Medicines Agency recommends precautionary recall of batches of clopidogrel-containing medicines from Acino Pharma GmbH.  http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2010/03/news_detail_001010.jsp&murl=menus/news_and_events/news_and_events.jsp&mid=WC0b01ac058004d5c1
    12. EudaGMDP Noncompliance Report at http://eudragmdp.ema.europa.eu/inspections/gmpc/searchGMPNonCompliance.do
    13. FDA Warning Letters: http://www.fda.gov/iceci/enforcementactions/WarningLetters/default.htm
    14. FDA Import Alert List, http://www.accessdata.fda.gov/cms_ia/importalert_189.html


    Helena Champion has over 25 years of U.S. and international experience in biotechnology, biologics and small molecule drug substance and drug product development and manufacture, gained from many years in product development and Quality Assurance, most recently as Quality Assurance Director at Wyeth Biotech External Supply/Pfizer, preceded by Biogen Idec. She has an MS from the University of Guelph, Ontario, Canada, and an MBA from Northeastern University, Boston, MA, USA.
    Related Searches
    • Manufacturing
    • Pharma
    • Development
    • Sterile
    Suggested For You
    Mogene Mogene
    Recro Gainesville Expands Mfg. Capabilities Recro Gainesville Expands Mfg. Capabilities
    Diverse Products And Technologies Delivered Diverse Products And Technologies Delivered
    PPD Expands Vaccine Development Lab PPD Expands Vaccine Development Lab
    UPM Celebrates 100-Years of Mfg. at Tennessee Site UPM Celebrates 100-Years of Mfg. at Tennessee Site
    Novartis in $225M Cardiovascular Deal With Ionis Novartis in $225M Cardiovascular Deal With Ionis
    IMAB Licenses Phase II Ferring Compound IMAB Licenses Phase II Ferring Compound
    Genmab Achieves $30M Janssen Milestone  Genmab Achieves $30M Janssen Milestone
    Adamis Pharma Acquires US Compounding Adamis Pharma Acquires US Compounding
    Are Your Nutritional Supplements Safe? Are Your Nutritional Supplements Safe?
    Contract Manufacturing: Setting Standards in the Supplement Industry Contract Manufacturing: Setting Standards in the Supplement Industry
    Contamination Issues in Today’s Injectables Market Contamination Issues in Today’s Injectables Market
    cGMP Enforcement, the False Claims Act and Lessons From Omnicare cGMP Enforcement, the False Claims Act and Lessons From Omnicare
    Impax Labs Names Technical Ops SVP Impax Labs Names Technical Ops SVP

    Related Features

    • Clinical Trials | Information Technology | R&D
      Decentralized Trials Fuel AI Revolution in Clinical Research

      Decentralized Trials Fuel AI Revolution in Clinical Research

      The life sciences industry is giving clinical a full makeover, dramatically improving how new therapeutics are developed.
      Nick Moss, Vice President of Analytics and Machine Learning, Medable 11.17.20

    • Biologics, Proteins, Vaccines | Biosimilars | Drug Development
      Biopharma Contract Manufacturing: Robust Growth Ahead

      Biopharma Contract Manufacturing: Robust Growth Ahead

      The biopharmaceutical contract manufacturing market is projected to reach $6.3 billion in 2020, and it will continue to grow over the next five years.
      William Downey, HighTech Business Decisions 11.17.20

    • Clinical Trials | Information Technology
      The Role of Electronic Monitoring in Maintaining Medication Adherence

      The Role of Electronic Monitoring in Maintaining Medication Adherence

      Digital solutions offer hope to get patients to take their medications properly.
      Bernard Vrijens, Scientific Lead, AARDEX Group 10.14.20


    • Biosimilars
      Biosimilar Manufacturing Strategies

      Biosimilar Manufacturing Strategies

      Five steps to competing in a post-patent expiry era.
      George I’ons, Owen Mumford Pharmaceutical Services 09.09.20

    • Biosimilars
      The U.S. Biosimilars Market: Shaking the “Laggard” Label

      The U.S. Biosimilars Market: Shaking the “Laggard” Label

      Biosimilar uptake set to reshape the U.S. market
      Katya Svoboda and Bob Swann, ICON 05.05.20

    • Biologics, Proteins, Vaccines | Biosimilars
      Biopharma Over 20 Years

      Biopharma Over 20 Years

      A look at the key trends that have impacted the biopharma industry over the years.
      K. John Morrow, Jr. and Eric S. Langer, BioPlan Associates 11.20.19


    • Clinical Trials
      Gene Therapy Trials

      Gene Therapy Trials

      Applications and the limitations of real-world data.
      Karen Ooms, Executive Vice President and Head of Statistics, Quanticate 09.16.19

    • Biologics, Proteins, Vaccines | Biosimilars
      Are Biotech Companies Strong Investments?

      Are Biotech Companies Strong Investments?

      Biotech capital raised via IPO has increased dramatically over the past couple of years.
      Jason Monteleone , CEO, Clinipace 05.07.19

    • Clinical Trials | Information Technology
      The New Horizon: Metaprise Analytics in Life Sciences

      The New Horizon: Metaprise Analytics in Life Sciences

      Going beyond enterprise analytics to metaprise analytics—patient-centric systems that create a data driven trial team.
      Michelle Longmire, MD, CEO and Founder, Medable 05.07.19


    • Clinical Trials
      Clinical Trial Feasibility

      Clinical Trial Feasibility

      How to reduce late-stage trial risk with feasibility analysis
      Alan Scott and Denis McMillan, PAREXEL International 04.05.19

    • Clinical Trial Materials | Clinical Trials | Supply Chain
      Optimizing Clinical Supply Management

      Optimizing Clinical Supply Management

      IRT system design strategies to help life science companies cut drug wastage across clinical programs.
      Bart Nicholson, Director of Customer Success for IRT, CRF Bracket 04.05.19

    • Clinical Trials | R&D
      Improving Pharma R&D Efficiency: The need to transform clinical trials

      Improving Pharma R&D Efficiency: The need to transform clinical trials

      Cost pressures on drug development are driving the search for savings and efficiencies—but efforts need to be integrated if t
      ICON plc 10.10.18


    • Biosimilars
      Biosimilar  Market Trends

      Biosimilar Market Trends

      2017 was a record year for biosimilar approvals.
      Fiona Greer and Bruno Speder, SGS 09.11.18

    • Biologics, Proteins, Vaccines | Biosimilars | Drug Development
      Haste Makes Waste

      Haste Makes Waste

      When to sprint and when to breathe in the race from lab to clinic.
      Christian Cattaruzza, MilliporeSigma 09.11.18

    • Biologics, Proteins, Vaccines | Biosimilars
      Biopharma Manufacturing Markets

      Biopharma Manufacturing Markets

      Biomanufacturing contract services and supplies markets continue to expand
      Ronald A. Rader and Eric S. Langer, BioPlan Associates 05.08.18

    Trending
    • Integrated Continuous Manufacturing ICM
    • Pfizer, BioNTech Enter Vax Pact With COVAX
    • CONTINUUS Awarded $69.3M DoD Grant
    • Nexelis Acquires GSK Vax Lab In Marburg
    • Piramal Inks Clinical Supply Deal With Theratechnologies
    Breaking News
    • Pfizer, BioNTech Enter Vax Pact with COVAX
    • FDA Approves Janssen’s CABENUVA
    • AGC Biologics Appoints Boulder Site GM
    • Lilly Completes $1B Acquisition of Prevail
    • Top BioPharma Form Accumulus Synergy
    View Breaking News >
    CURRENT ISSUE

    November/December 2020

    • Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up
    • Ensuring Quality During the Transfer and Scale Up of Rx Drugs
    • Inspecting the Unexpected
    • Cold Chain Trends
    • Catering for the Complex
    • Biopharma Contract Manufacturing: Robust Growth Ahead
    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    • The Single-Use Mixing Landscape: Evaluating Your Options
    • Self-Medication: Flexibility for Patients and Drug Manufacturers
    • Decentralized Trials Fuel AI Revolution in Clinical Research
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    NIH Study Compares Low-Fat, Plant-based to Low-Carb, Animal-Based Diet
    Gadot Positions Mineral Line for Vegan Market
    Nutritfy India to Launch Global Broadcast Channel Covering Nutrition
    Coatings World

    Latest Breaking News From Coatings World

    LINE-X Launches Dealer Program with International Truck
    PPG Reports Q4, Full-year 2020 Financial Results
    BASF Begins Implementing Ralignment of Global Business Services Unit
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Cretex Companies CEO Steps Down
    Data Show Porex's Medical Device Filtration Materials Protect Against Virus, Bacteria Spread
    Endoscopic Hemostasis Devices Market Valued at $730 Million
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Pfizer, BioNTech Enter Vax Pact with COVAX
    FDA Approves Janssen’s CABENUVA
    AGC Biologics Appoints Boulder Site GM
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Coty Appoints Chief Procurement Officer
    Lageen Tubes Launches Mono-Material PE Tube Solutions
    Jason Jones Loses Battle with Covid-19
    Happi

    Latest Breaking News From Happi

    Carol’s Daughter Adds New Hair Products
    Moroccan Gold Series Launches NuDo Shampoo
    Youbody Debuts Waterless Body Wash
    Ink World

    Latest Breaking News From Ink World

    BOBST Demonstrates Future of Flexible Packaging Production at Virtual Open House
    Morancé Soudure France Adds Comexi F2 MC 10-color Flexo Press
    AR Packaging Acquiring Firstan Holdings Ltd
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Gallus planning virtual event for March
    Lemu Group engineers mask-making machine
    Niagara Label upgrades with Nilpeter flexo press
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Freudenberg to Establish Apparel Interlining Competence Centers
    Minet Adds Spunlace Line in Romania
    Lemu Group Engineers Mask-Making Machine
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Cretex Companies CEO Steps Down
    Conformis Enters Development & Supply Agreement with SITES Medical
    Sectra, RSA Biomedical Sign Distribution Agreement for Implant Stability Tool
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    UDC Subsidiary Adesis' Website Wins 2020 MarCom Platinum Award
    Ambiq Wins IoT Semiconductor Company of the Year Award
    Ynvisible Names Michael Robinson CEO, Jani-Mikael Kuusisto SVP Ventures

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login